[en] The authors discuss the results obtained on 51 patients treated with the Xsight Lung Tracking System (which do not need fiducial) for non-small-cell lung carcinomas. Results are analyzed and discussed in terms of gross tumour volume, session duration, survival rate by one year or two years, local control rate, later diagnosis (pneumopathy, lung fibrosis), and toxicity. These results suggest that this treatment mode could be an interesting option for non-operable patients. Short communication

[en] We intend to take stock of the situation of knowledge on association of anti angiogenic molecules with ionizing radiation: its rational, its feasibility, its clinical interest and its toxicity. (N.C.)

[en] A Siemens electronic portal imaging system called Beamview^plusTM was used daily in 15 lung cancer patients for each X-ray field. Out of the 714 expected portal images, 585 (82%), were obtained and printed. We counted 94 errors in the 585 successful controls (16 %). Four main classes of errors were identified: irradiation field placement (47 cases, 50 %), shielding placement (30 cases, 32 %), patients's position on the tilt examining table (14 cases, 15 %), and selection of the energy (3 cases, (3 %). Forty percent of these errors were potentially serious in terms of treatment volume and vital organ protection. Only portal imaging control could easily detect errors because they occurred randomly. We thus consider the use of this daily system helpful for patient management. (author)

[en] CyberKnife is a recent stereotactic radiotherapy technique which allows the treatment of hepatic lesions while performing tumour tracking. This high precision allows the delivered dose to be increased. The authors report the use of this technique for the treatment of primitive and secondary hepatic lesions (hepato-carcinoma, hepatic metastases, cholangio-carcinoma). Results are discussed in terms of tolerance, toxicity, induced lesion, local control, and global survival. This technique is not much invasive: this is one of its advantages. But its place within a strategy and the optimal sequence are still to be defined. Short communication

[en] The stereotactic radiotherapy by cyberknife automated accelerator allows to consider a short and well tolerated treatment of latero-pelvic recurrences in irradiated place in unresectable patients in situation of therapy deadlock. The efficiency and the toxicities must be evaluated at long term but the first results seem promising. (N.C.)

No abstract available

[en] The fractionated stereotactic radiotherapy by Cyberknife is an option in the treatment of eyes tumors. The advantages of the Cyberknife in the choroid melanomas are in its infra-millimetric precision, to the automated repositioning on the skull bones and to the conformity brought by the stereotaxy. The objective of this study was to validate the quality of repositioning and the immobility of the eyes with closed eyelids. Conclusion: the reproducibility of the eye positioning with closed eyelids seems enough to consider the conservative treatment of choroid melanomas by fractionated stereotactic radiotherapy by Cyberknife without implementation of fiducials nor retrobulbar anaesthesia. (N.C.)

[en] The generalisation of the three dimensional conformal radiotherapy, then the conformal radiotherapy with intensity modulation, the receipt of a dosimetry scanner, two tomo-therapy devices and a cyberknife modified deeply our practices. The delineation of every organ at risk and the prescription of constraints to organs at risk became systematic. The new technologies by their possibilities in term of accuracy, conformity and tracking lead us to choose new therapy indications in situations where the control of dose to organs at risk is particularly crucial (hypo fractionated intra and extra cranial stereotaxic). This context make us feel the necessity to use a data base of constraints to organs at risk, for the classic fractionation and the hypo fractionation. An array containing all the data has been published as posters, it is displayed in large format in the work area for doctors in the area of simulation and data acquisition as well as dosimetry. (N.C.)

[en] Between 1979 and 1990, 149 patients with non-metastatic thymomas were treated in ten French cancer centers. Patients were staged according to the 'GETT' classification, derived from that of Masaoka. There were 13 stage I patients, 46 stage II, 58 stage III and 32 stage IVA. Gross total resections were performed in 63 cases, subtotal resections in 31 cases and in 55 cases a biopsy alone was performed. All patients received radiotherapy and 74 were given post-operative chemotherapy. Median follow-up was 7.7 years. Local control was achieved in 117 cases (78.5%) and was influenced by the stage of the disease (p < 0.01) and the extent of surgery (p < 0.01). Twenty-six patients developed metastatis after a median period of 9 months. Five- and ten-year disease-free survival rates were 59.5% (51-67%) and 49.5% (39-60%), respectively, and were influenced by the stage of the disease (p < 0.01), the extent of surgery (p < 0.001) and a mediastinal compression on presentation (p = 5 x 10^-6). Four factors could predict a worse overall survival in the multivariate analysis: mediastinal compression on presentation (p < 0.001), absence of chemotherapy (p < 0.001), biopsy alone (p = 0.003), and young age (p = 0.013). A worse DFS was predicted by mediastinal compression on presentation (p < 0.001), absence of chemotherapy (p < 0.001), young age (p 0.006), and stages III-IVA (p = 0.04). Future therapeutic strategies are discussed and the literature is reviewed

[en] In June 2007, the CyberKnife has been implemented at Centre Oscar-Lambret in Lille. The program has been developed around specific clinical indications: head and neck reirradiation, liver. Early results are presented. The system includes several way of repositioning fixed targets and tracking moving targets with breathing. With each way, there is a dedicated tool for the quality control. (authors)